Monocytes from HIV-infected individuals show impaired cholesterol efflux and increased foam cell formation after transendothelial migration

AIDS

Volumn 29, Issue 12, 2015, Pages 1445-1457

  Maisa, Anna ^a   Hearps, Anna C ^a,b   Angelovich, Thomas A ^a,c   Pereira, Candida F ^a,b   Zhou, Jingling ^a   Shi, Margaret D Y ^a,d   Palmer, Clovis S ^a   Muller, William A ^e   Crowe, Suzanne M ^a,b   Jaworowski, Anthony ^a,b  

^a BURNET INSTITUTE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c RMIT UNIVERSITY   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Atherosclerosis; Cholesterol efflux; Foam cells; HIV; Innate immune activation; Macrophage; Monocytes

Indexed keywords

ABC TRANSPORTER A1; BLOCKING ANTIBODY; CHOLESTEROL; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; ANTIVIRAL THERAPY; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CELL DIFFERENTIATION; CHOLESTEROL METABOLISM; CHOLESTEROL TRANSPORT; CHRONIC INFLAMMATION; CLINICAL ARTICLE; CONTROLLED STUDY; FOAM CELL; GENE EXPRESSION; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; MACROPHAGE ACTIVATION; MALE; MONOCYTE; PHENOTYPE; PRIORITY JOURNAL; SERUM; TRANSENDOTHELIAL AND TRANSEPITHELIAL MIGRATION; VIRUS LOAD; CELL CULTURE; COMPLICATION; METABOLISM; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; THEORETICAL MODEL; TRANSPORT AT THE CELLULAR LEVEL;

ADULT; ATHEROSCLEROSIS; BIOLOGICAL TRANSPORT; CELL DIFFERENTIATION; CELLS, CULTURED; CHOLESTEROL; FOAM CELLS; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; MODELS, THEORETICAL; MONOCYTES; TRANSENDOTHELIAL AND TRANSEPITHELIAL MIGRATION;

EID: 84942583775     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000739     Document Type: Article

References (53)

1. Marin B, Thiebaut R, Bucher HC, Rondeau V, Costagliola D, Dorrucci M, et al. Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy. AIDS 2009; 23:1743-1753.
2. Rodger AJ, Lodwick R, Schechter M, Deeks S, Amin J, Gilson R, et al. Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population. AIDS 2013; 27:973-979.
3. Hsue PY, Hunt PW, Schnell A, Kalapus SC, Hoh R, Ganz P, et al. Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-Associated atherosclerosis. AIDS 2009; 23:1059-1067.
4. Lo J, Abbara S, Shturman L, Soni A, Wei J, Rocha-Filho JA, et al. Increased prevalence of subclinical coronary atherosclerosis detected by coronary computed tomography angiography in HIV-infected men. AIDS 2010; 24:243-253.
5. Currier JS, Taylor A, Boyd F, Dezii CM, Kawabata H, Burtcel B, et al. Coronary heart disease in HIV-infected individuals. J Acquir Immune Defic Syndr 2003; 33:506-512.
6. Obel N, Thomsen HF, Kronborg G, Larsen CS, Hildebrandt PR, Sorensen HT, et al. Ischemic heart disease in HIV-infected and HIV-uninfected individuals: a population-based cohort study. Clin Infect Dis 2007; 44:1625-1631.
7. Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 2007; 92:2506-2512.
8. Freiberg MS, Chang CC, Kuller LH, Skanderson M, Lowy E, Kraemer KL, et al. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med 2013; 173:614-622.
9. Hsue PY, Lo JC, Franklin A, Bolger AF, Martin JN, Deeks SG, et al. Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation 2004; 109:1603-1608.
10. Lorenz MW, Stephan C, Harmjanz A, Staszewski S, Buehler A, Bickel M, et al. Both long-term HIV infection and highly active antiretroviral therapy are independent risk factors for early carotid atherosclerosis. Atherosclerosis 2008; 196:720-726.
11. Parra S, Coll B, Aragones G, Marsillach J, Beltran R, Rull A, et al. Nonconcordance between subclinical atherosclerosis and the calculated Framingham risk score in HIV-infected patients: relationships with serum markers of oxidation and inflammation. HIV Med 2010; 11:225-231.
12. Friis-Moller N, Sabin CA, Weber R, d'Arminio Monforte A, El-Sadr WM, Reiss P, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349:1993-2003.
13. Islam FM, Wu J, Jansson J, Wilson DP. Relative risk of cardiovascular disease among people living with HIV: a systematic review and meta-Analysis. HIV Medicine 2012; 13:453-468.
14. Currier JS, Lundgren JD, Carr A, Klein D, Sabin CA, Sax PE, et al. Epidemiological evidence for cardiovascular disease in HIVinfected patients and relationship to highly active antiretroviral therapy. Circulation 2008; 118:e29-e35.
15. El-Sadr WM, Lundgren J, Neaton JD, Gordin F, Abrams D, Arduino RC, et al. CD4R count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283-2296.
16. Pereyra F, Lo J, Triant VA, Wei J, Buzon MJ, Fitch KV, et al. Increased coronary atherosclerosis and immune activation in HIV-1 elite controllers. AIDS 2012; 26:2409-2412.
17. Hsue PY, Scherzer R, Hunt PW, Schnell A, Bolger AF, Kalapus SC, et al. Carotid intima-media thickness progression in HIVinfected adults occurs preferentially at the carotid bifurcation and is predicted by inflammation. J Am Heart Assoc 2012; 1:jah3-e000422. doi: 10.1161.
18. Duprez DA, Neuhaus J, Kuller LH, Tracy R, Belloso W, De Wit S, et al. Inflammation, coagulation and cardiovascular disease in HIV-infected individuals. PLoS One 2012; 7:e44454.
19. De Luca A, de Gaetano Donati K, Colafigli M, Cozzi-Lepri A, De Curtis A, Gori A, et al. The association of high-sensitivity c-reactive protein and other biomarkers with cardiovascular disease in patients treated for HIV: a nested case-control study. BMC Infect Dis 2013; 13:414.
20. Hearps AC, Maisa A, Cheng WJ, Angelovich TA, Lichtfuss GF, Palmer CS, et al. HIV infection induces age-related changes to monocytes and innate immune activation in young men that persist despite combination antiretroviral therapy. AIDS 2012; 26:843-853.
21. Martin GE, Gouillou M, Hearps AC, Angelovich TA, Cheng AC, Lynch F, et al. Age-Associated changes in monocyte and innate immune activation markers occur more rapidly in HIV infected women. PLoS One 2013; 8:e55279.
22. Burdo TH, Lo J, Abbara S, Wei J, Delelys ME, Preffer F, et al. Soluble CD163, a novel marker of activated macrophages, is elevated and associated with noncalcified coronary plaque in HIV-infected patients. J Infect Dis 2011; 204:1227-1236.
23. Subramanian S, Tawakol A, Burdo TH, Abbara S, Wei J, Vijayakumar J, et al. Arterial inflammation in patients with HIV. JAMA 2012; 308:379-386.
24. Kelesidis T, Kendall MA, Yang OO, Hodis HN, Currier JS. Biomarkers of microbial translocation and macrophage activation: association with progression of subclinical atherosclerosis in HIV-1 infection. J Infect Dis 2012; 206:1558-1567.
25. Westhorpe CL, Maisa A, Spelman T, Hoy JF, Dewar EM, Karapanagiotidis S, et al. Associations between blood monocyte markers and carotid atherosclerosis in HIV-positive patients. Immunol Cell Biol 2014; 92:133-138.
26. Baker JV, Hullsiek KH, SinghA,Wilson E,Henry K, Lichtenstein K, et al. Immunologic predictors of coronary artery calcium progression in a contemporary HIV cohort. AIDS 2014; 28:831-840.
27. Funderburg NT, Zidar DA, Shive C, Lioi A, Mudd J, Musselwhite LW, et al. Shared monocyte subset phenotypes in HIV-1 infection and in uninfected subjects with acute coronary syndrome. Blood 2012; 120:4599-4608.
28. Lusis AJ. Atherosclerosis. Nature 2000; 407:233-241.
29. Febbraio M, Silverstein RL. CD36: implications in cardiovascular disease. Int J Biochem Cell Biol 2007; 39:2012-2030.
30. Park YM, Febbraio M, Silverstein RL. CD36 modulates migration of mouse and human macrophages in response to oxidized LDL and may contribute to macrophage trapping in the arterial intima. J Clin Invest 2009; 119:136-145.
31. Galkina E, Ley K. Immune and inflammatory mechanisms of atherosclerosis (M). Annu Rev Immunol 2009; 27:165-197.
32. Llodra J, Angeli V, Liu J, Trogan E, Fisher EA, Randolph GJ. Emigration of monocyte-derived cells from atherosclerotic lesions characterizes regressive, but not progressive, plaques. Proc Natl Acad Sci U S A 2004; 101:11779-11784.
33. Muller WA, Weigl SA. Monocyte-selective transendothelial migration: dissection of the binding and transmigration phases by an in vitro assay. J Exp Med 1992; 176:819-828.
34. Randolph GJ, Furie MB. A soluble gradient of endogenous monocyte chemoattractant protein-1 promotes the transendothelial migration of monocytes in vitro. J Immunol 1995; 155:3610-3618.
35. Westhorpe CLV, Dufour EM, Maisa A, Jaworowski A, Crowe SM, Muller WA. Endothelial cell activation promotes foam cell formation by monocytes following transendothelial migration in an in vitro model. Exp Mol Pathol 2012; 93:220-226.
36. Westhorpe CL, Zhou J, Webster NL, Kalionis B, Lewin SR, Jaworowski A, et al. Effects of HIV-1 infection in vitro on transendothelial migration by monocytes and monocyte-derived macrophages. J Leukoc Biol 2009; 85:1027-1035.
37. Angelovich TA, Hearps AC, Jaworowski A. Inflammationinduced foam cell formation in chronic inflammatory disease. Immunol Cell Biol 2015. doi: 10.1038/icb.2015.26.
38. Cassol E, Malfeld S, Mahasha P, van der Merwe S, Cassol S, Seebregts C, et al. Persistent microbial translocation andimmune activation in HIV-1-infected South Africans receiving combination antiretroviral therapy. J Infect Dis 2010; 202:723-733.
39. Souza SJ, Luzia LA, Santos SS, Rondo PH. Lipid profile of HIVinfected patients in relation to antiretroviral therapy: a review. Rev Assoc Med Bras 2013; 59:186-198.
40. Feeney ER, McAuley N, O'Halloran JA, Rock C, Low J, Satchell CS, et al. The expression of cholesterol metabolism genes in monocytes from HIV-infected subjects suggests intracellular cholesterol accumulation. J Infect Dis 2013; 207:628-637.
41. Maslin CL, Kedzierska K, Webster NL, Muller WA, Crowe SM. Transendothelial migration of monocytes: the underlying molecular mechanisms and consequences of HIV-1 infection. Curr HIV Res 2005; 3:303-317.
42. Ross AC, Rizk N, O'Riordan MA, Dogra V, El-Bejjani D, Storer N, et al. Relationship between inflammatory markers, endothelial activation markers, and carotid intima-media thickness in HIV-infected patients receiving antiretroviral therapy. Clin Infect Dis 2009; 49:1119-1127.
43. Zietz C, Hotz B, Sturzl M, Rauch E, Penning R, Lohrs U. Aortic endothelium in HIV-1 infection: chronic injury, activation, and increased leukocyte adherence. Am J Pathol 1996; 149:1887-1898.
44. Hearps AC, Martin GE, Rajasuriar R, Crowe SM. Inflammatory co-morbidities in HIVR individuals: learning lessons from healthy ageing. Curr HIV/AIDS Rep 2014; 11:20-34.
45. Mujawar Z, Rose H, Morrow MP, Pushkarsky T, Dubrovsky L, Mukhamedova N, et al. Human immunodeficiency virus impairs reverse cholesterol transport from macrophages. PLoS Biol 2006; 4:e365.
46. Bernard MA, Han X, Inderbitzin S, Agbim I, Zhao H, Koziel H, et al. HIV-derived ssRNA binds to TLR8 to induce inflammation-driven macrophage foam cell formation. PLoS One 2014; 9:e104039.
47. Raymond AD, Campbell-Sims TC, Khan M, Lang M, Huang MB, Bond VC, et al. HIV Type 1 Nef is released from infected cells in CD45(R) microvesicles and is present in the plasma of HIVinfected individuals. AIDS Res Hum Retroviruses 2011; 27:167-178.
48. Fitch KV, Srinivasa S, Abbara S, Burdo TH, Williams KC, Eneh P, et al. Noncalcified coronary atherosclerotic plaque and immune activation in HIV-infected women. J Infect Dis 2013; 208:1737-1746.
49. Maiguel D, Faridi MH, Wei C, Kuwano Y, Balla KM, Hernandez D, et al. Small molecule-mediated activation of the integrin CD11b/CD18 reduces inflammatory disease. Sci Signal 2011; 4:ra57.
50. Kapinsky M, Torzewski M, Buchler C, Duong CQ, Rothe G, Schmitz G. Enzymatically degraded LDL preferentially binds to CD14(high) CD16(R) monocytes and induces foam cell formation mediated only in part by the class B scavengerreceptor CD36. Arterioscler Thromb Vasc Biol 2001; 21:1004-1010.
51. Feng J, Han J, Pearce SF, Silverstein RL, Gotto AM Jr., Hajjar DP, et al. Induction of CD36 expression by oxidized LDL and IL-4 by a common signaling pathway dependent on protein kinase C and PPAR-gamma. J Lipid Res 2000; 41:688-696.
52. Hirano K, Yamashita S, Nakagawa Y, Ohya T, Matsuura F, Tsukamoto K, et al. Expression of human scavenger receptor class B type I in cultured human monocyte-derived macrophages and atherosclerotic lesions. Circ Res 1999; 85: 108-116.
53. Nakata A, Nakagawa Y, Nishida M, Nozaki S, Miyagawa J, Nakagawa T, et al. CD36, a novel receptor for oxidized lowdensity lipoproteins, is highly expressed on lipid-laden macrophages in human atherosclerotic aorta. Arterioscler Thromb Vasc Biol 1999; 19:1333-1339.